In a phase II study, the use of maintenance sunitinib improved progression-free survival among patients with untreated extensive-stage small-cell lung cancer.
A single-institution study found that patients with melanomas of 4 mm thickness who had a negative sentinel lymph node biopsy had significantly prolonged survival.
Metastatic renal cell carcinoma patients with an elevated neutrophil-to-lymphocyte ratio at baseline had inferior outcomes compared those with a low ratio.
